《碳青霉烯耐药革兰阴性杆菌感染预防与控制技术指引》解读

2020-04-25 微生物与感染.2020.15(2):71-75.

细菌耐药是全球关注的公共卫生问题,给人类健康、发展和安全造成根本性威胁。因此采取积极有效的控制策略和措施、预防和控制多重耐药菌感染的发生与传播具有现实紧迫性,势在必行。近期,中华预防医学会医院感染控制

中文标题:

《碳青霉烯耐药革兰阴性杆菌感染预防与控制技术指引》解读

发布机构:

发布日期:

2020-04-25

简要介绍:

细菌耐药是全球关注的公共卫生问题,给人类健康、发展和安全造成根本性威胁。因此采取积极有效的控制策略和措施、预防和控制多重耐药菌感染的发生与传播具有现实紧迫性,势在必行。近期,中华预防医学会医院感染控制分会、中华医学会感染病学分会、中国医院协会医院感染管理专业委员会、中国老年医学学会感染管理质量控制分会、中华护理学会医院感染管理专业委员会、国家医院感染管理专业质控中心联合发布了《碳青霉烯耐药革兰阴性杆菌感染预防与控制技术指引》(下文简称《指引》),对碳青霉烯耐药革兰阴性杆菌的医院感染精准防控提出了建议,内容包括集束化措施、合理使用抗菌药物、手卫生、主动监测、接触预防、患者隔离和环境清洁消毒。为更好地理解和落实《指引》,本文对其进行解读,期望对临床工作有一定的指导作用。

相关资料下载:
[AttachmentFileName(sort=1, fileName=《碳青霉烯耐药革兰阴性杆菌感染预防与控制技术指引》解读.pdf)] GetToolGuiderByIdResponse(projectId=1, id=d42bd1c001910e00, title=《碳青霉烯耐药革兰阴性杆菌感染预防与控制技术指引》解读, enTitle=, guiderFrom=微生物与感染.2020.15(2):71-75., authorId=0, author=, summary=细菌耐药是全球关注的公共卫生问题,给人类健康、发展和安全造成根本性威胁。因此采取积极有效的控制策略和措施、预防和控制多重耐药菌感染的发生与传播具有现实紧迫性,势在必行。近期,中华预防医学会医院感染控制, cover=https://img.medsci.cn/2020529/1590684554016_2020535.jpg, journalId=0, articlesId=null, associationId=0, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Sat Apr 25 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #333333;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>细菌耐药是全球关注的公共卫生问题,给人类健康、发展和安全造成根本性威胁。因此采取积极有效的控制策略和措施、预防和控制多重耐药菌感染的发生与传播具有现实紧迫性,势在必行。近期,中华预防医学会医院感染控制分会、中华医学会感染病学分会、中国医院协会医院感染管理专业委员会、中国老年医学学会感染管理质量控制分会、中华护理学会医院感染管理专业委员会、国家医院感染管理专业质控中心联合发布了《碳青霉烯耐药革兰阴性杆菌感染预防与控制技术指引》(下文简称《指引》),对碳青霉烯耐药革兰阴性杆菌的医院感染精准防控提出了建议,内容包括集束化措施、合理使用抗菌药物、手卫生、主动监测、接触预防、患者隔离和环境清洁消毒。为更好地理解和落实《指引》,本文对其进行解读,期望对临床工作有一定的指导作用。</p> </div> </div> </div>, tagList=[TagDto(tagId=846, tagName=感染), TagDto(tagId=1256, tagName=耐药菌)], categoryList=[CategoryDto(categoryId=9, categoryName=感染, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=846, guiderKeyword=感染, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2557, appHits=341, showAppHits=26, pcHits=776, showPcHits=2235, likes=3, shares=13, comments=7, approvalStatus=1, publishedTime=Fri May 29 01:53:36 CST 2020, publishedTimeString=2020-04-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Fri May 29 00:49:19 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 12:38:57 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《碳青霉烯耐药革兰阴性杆菌感染预防与控制技术指引》解读.pdf)])
《碳青霉烯耐药革兰阴性杆菌感染预防与控制技术指引》解读.pdf
下载请点击:
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2190643, encodeId=2051219064394, content=我咋点不开?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de825692974, createdName=ms2000001190486449, createdTime=Sat Mar 02 21:56:33 CST 2024, time=2024-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233042, encodeId=733112330420a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=44d05587752, createdName=ms6000000896753037, createdTime=Sun Jul 17 21:33:54 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191316, encodeId=48d9119131645, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Wed Feb 09 08:08:44 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004932, encodeId=967910049323d, content=非常受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/baaeb5ce73494a3a80e589efffc040a2/0d3de824477643ca8a7463079792bab9.jpg, createdBy=06a95228663, createdName=14796b58m13暂无昵称, createdTime=Tue Aug 03 18:26:58 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971122, encodeId=7c5f9e112215, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210605/5941cc41a226481ba97bb9959426a377/94ec9bcdf2a4402dbb5bd76b249f1042.jpg, createdBy=32501422575, createdName=吕小小, createdTime=Sat Jun 05 14:18:09 CST 2021, time=2021-06-05, status=1, ipAttribution=)]
    2024-03-02 ms2000001190486449 来自山东省

    我咋点不开?

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2190643, encodeId=2051219064394, content=我咋点不开?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de825692974, createdName=ms2000001190486449, createdTime=Sat Mar 02 21:56:33 CST 2024, time=2024-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233042, encodeId=733112330420a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=44d05587752, createdName=ms6000000896753037, createdTime=Sun Jul 17 21:33:54 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191316, encodeId=48d9119131645, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Wed Feb 09 08:08:44 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004932, encodeId=967910049323d, content=非常受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/baaeb5ce73494a3a80e589efffc040a2/0d3de824477643ca8a7463079792bab9.jpg, createdBy=06a95228663, createdName=14796b58m13暂无昵称, createdTime=Tue Aug 03 18:26:58 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971122, encodeId=7c5f9e112215, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210605/5941cc41a226481ba97bb9959426a377/94ec9bcdf2a4402dbb5bd76b249f1042.jpg, createdBy=32501422575, createdName=吕小小, createdTime=Sat Jun 05 14:18:09 CST 2021, time=2021-06-05, status=1, ipAttribution=)]
    2022-07-17 ms6000000896753037

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2190643, encodeId=2051219064394, content=我咋点不开?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de825692974, createdName=ms2000001190486449, createdTime=Sat Mar 02 21:56:33 CST 2024, time=2024-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233042, encodeId=733112330420a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=44d05587752, createdName=ms6000000896753037, createdTime=Sun Jul 17 21:33:54 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191316, encodeId=48d9119131645, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Wed Feb 09 08:08:44 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004932, encodeId=967910049323d, content=非常受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/baaeb5ce73494a3a80e589efffc040a2/0d3de824477643ca8a7463079792bab9.jpg, createdBy=06a95228663, createdName=14796b58m13暂无昵称, createdTime=Tue Aug 03 18:26:58 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971122, encodeId=7c5f9e112215, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210605/5941cc41a226481ba97bb9959426a377/94ec9bcdf2a4402dbb5bd76b249f1042.jpg, createdBy=32501422575, createdName=吕小小, createdTime=Sat Jun 05 14:18:09 CST 2021, time=2021-06-05, status=1, ipAttribution=)]
    2022-02-09 ms5000000254917531

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2190643, encodeId=2051219064394, content=我咋点不开?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de825692974, createdName=ms2000001190486449, createdTime=Sat Mar 02 21:56:33 CST 2024, time=2024-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233042, encodeId=733112330420a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=44d05587752, createdName=ms6000000896753037, createdTime=Sun Jul 17 21:33:54 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191316, encodeId=48d9119131645, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Wed Feb 09 08:08:44 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004932, encodeId=967910049323d, content=非常受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/baaeb5ce73494a3a80e589efffc040a2/0d3de824477643ca8a7463079792bab9.jpg, createdBy=06a95228663, createdName=14796b58m13暂无昵称, createdTime=Tue Aug 03 18:26:58 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971122, encodeId=7c5f9e112215, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210605/5941cc41a226481ba97bb9959426a377/94ec9bcdf2a4402dbb5bd76b249f1042.jpg, createdBy=32501422575, createdName=吕小小, createdTime=Sat Jun 05 14:18:09 CST 2021, time=2021-06-05, status=1, ipAttribution=)]
    2021-08-03 14796b58m13暂无昵称

    非常受益

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2190643, encodeId=2051219064394, content=我咋点不开?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de825692974, createdName=ms2000001190486449, createdTime=Sat Mar 02 21:56:33 CST 2024, time=2024-03-02, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1233042, encodeId=733112330420a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=44d05587752, createdName=ms6000000896753037, createdTime=Sun Jul 17 21:33:54 CST 2022, time=2022-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1191316, encodeId=48d9119131645, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57de6415950, createdName=ms5000000254917531, createdTime=Wed Feb 09 08:08:44 CST 2022, time=2022-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004932, encodeId=967910049323d, content=非常受益, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210803/baaeb5ce73494a3a80e589efffc040a2/0d3de824477643ca8a7463079792bab9.jpg, createdBy=06a95228663, createdName=14796b58m13暂无昵称, createdTime=Tue Aug 03 18:26:58 CST 2021, time=2021-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971122, encodeId=7c5f9e112215, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210605/5941cc41a226481ba97bb9959426a377/94ec9bcdf2a4402dbb5bd76b249f1042.jpg, createdBy=32501422575, createdName=吕小小, createdTime=Sat Jun 05 14:18:09 CST 2021, time=2021-06-05, status=1, ipAttribution=)]
    2021-06-05 吕小小

    学习了

    0

拓展阅读

2009 ESCMID:艰难梭菌感染 (CDI)治疗指南

欧洲临床微生物与感染性疾病学会(ESCMID,European Society of Clinical Microbiology and Infectious Diseases) · 2009-12-01

2009 皮肤及软组织感染诊断和治疗共识

中国医师协会皮肤科医师分会 · 2009-12-01

2010 OARAC 抗逆转录病毒药物使用指南:美国HIV感染孕妇(孕妇健康和减少围产期HIV传播)

艾滋病研究咨询理事会(OARAC,Office of AIDS Research Advisory Council) · 2010-01-01

2010 IDSA指南:成人与儿童复杂腹腔内感染的诊断与治疗

美国感染病学会(IDSA,Infectious Diseases Society of America) · 2010-01-01

2010 CDC 使用干扰素释放试验检测结核分枝杆菌感染:美国 2010

美国疾病控制与预防中心(CDC,Centers for Disease Control and Prevention) · 2010-01-01

2010UK在学校和其他幼儿设置的感染控制指引(猩红热)

英国健康保护局(HPA,Health Protection Agency) · 2010-01-01